
Supplementary Table 1 results of meta-analysis

Region	Subjects	Metabolites	No. of Studies	I^2	H ²	Z	P	SMD	95%CI
Hippocampus	MCLV- HC	mI	4	58.99%	2.44	1.08	0.28	0.23	-0.19 to 0.65
	MCI Vs HC	Glx/Cr	3	86.62%	7.47	-1.44	0.15	-0.76	-1.81 to 0.28
	AD Vs MCI	mI/Cr	4	29.18%	1.41	1.92	0.06	0.25	-0.01 to 0.50
	MCI	Cho/Cr	2	0.00%	0.03	-1.91	0.06	-0.47	-0.94 to 0.01
	MCI-converter Vs MCI-stable	NAA/Cr	2	17.31%	1.21	-0.72	0.47	-0.17	-0.65 to 0.30
		mI/NAA	3	76.15%	4.19	0.04	0.97	0.02	-0.79 to 0.82
	MCI Vs HC	Cho/Cr	17	89.01%	9.10	1.96	0.05	0.34	-0.00 to 0.69
		NAA/Cho	4	58.33%	2.40	-1.80	0.07	-0.35	-0.72 to 0.03
	AD Vs HC	Cr	4	73.18%	3.73	-1.71	0.09	-0.37	-0.80 to 0.05
PC	AD VS HC	Cho	6	50.97%	2.04	1.81	0.07	0.23	-0.02 to 0.48
PC		Cho/Cr	9	56.41%	2.29	0.79	0.43	0.10	-0.15 to 0.35
	AD Vs MCI	mI	4	0.00%	0.37	-0.69	0.49	-0.07	-0.28 to 0.13
		Cho	3	76.46%	4.25	-0.17	0.87	-0.05	-0.57 to 0.48
	MCI-converter Vs MCI-stable	NAA/Cr	2	0.00%	0.07	0.68	0.50	0.17	-0.33 to 0.67
	MICI-converter vs MICI-stable	Cho/Cr	2	0.00%	0.64	0.44	0.66	0.11	-0.39 to 0.61
	MCI Vs HC	NAA/Cr	3	0.00%	0.30	-0.81	0.42	-0.12	-0.40 to 0.17
Temporal lobe	AD Vs HC	Cho/Cr	3	19.57%	1.24	1.91	0.06	0.35	-0.01 to 0.71
	AD VS IIC	mI/Cr	4	0.00%	0.50	-1.87	0.06	-0.27	-0.57 to 0.01
	MCI Vs HC	NAA/Cr	3	0.00%	0.41	0.16	0.88	0.02	-0.2 to 0.24
Parietal lobe	MCI-converter Vs MCI-stable	Cho/Cr	2	35.30%	1.55	0.82	0.41	0.15	-0.21 to 0.50
	MICI-CONVENER VS MICI-Stable	NAA/mI	2	81.64%	5.45	-0.18	0.85	-0.08	-0.92 to 0.76
Occimital labo	AD Vs HC	NAA/Cr	3	0.00%	0.47	-1.69	0.09	-0.22	-0.47 to 0.04
Occipital lobe	AD VS HC	Cho/Cr	3	54.88%	2.22	1.08	0.28	0.22	-0.18 to 0.63


Region	Subjects	Metabolites	No. of Studies	I^2	H ²	Z	P	SMD	95%CI
Occipital lobe		Cho	3	43.21%	1.76	-0.80	0.42	-0.11	-0.40 to 0.17
	AD Vs HC	Cr	3	28.62%	1.40	-1.45	0.15	-0.21	-0.49 to 0.07
		mI	3	96.34%	27.29	1.09	0.28	1.09	-0.87 to 3.05
		NAA/Cr	3	83.86	6.20	-1.93	0.05	-0.98	-1.98 to 0.02
	MCI-converter Vs MCI-stable	mI/Cr	2	0.00%	0.68	-0.09	0.93	-0.02	-0.37 to 0.34
		NAA/mI	2	86.41%	7.36	-0.87	0.38	-0.44	-1.44 to 0.56
AC	MCI Vs HC	NAA/Cr	3	50.97%	2.04	-0.80	0.42	-0.20	-0.68 to 0.29
	AD Vs MCI	NAA/Cr	3	73.20%	3.73	-1.10	0.45	-0.25	-0.88 to 0.39
temporo-parietal lobe		NAA	3	32.36%	1.48	-0.93	0.35	-0.17	-0.51 to 0.18
	AD Vs HC	Cho	3	88.49%	8.69	0.89	0.37	0.51	-0.61 to 1.62
		Cr	3	0.00%	0.56	-0.55	0.59	-0.10	-0.44 to 0.25
Frontal WM	AD Vs HC	mI	3	68.55%	3.18	1.80	0.07%	0.64	-0.06 to 1.34
	AD VS TIC	NAA	3	47.43%	1.90	-0.80	0.42%	-0.15	-0.50 to 0.21
PWM	MCI Vs HC	Cho/Cr	3	0.00%	0.54	-0.01	0.99%	0.00	-0.26 to 0.25

HC: healthy controls, AD: Alzheimer's disease, MCI: Mild Cognitive Impairment, SMD: standardized mean difference, PC: posterior cingulate cortex, PWM: paratrigonal white matter, AC: anterior cingulate cortex, WM: white matter, NAA: N-Acetyl Aspartate, mI: myo-inositol, Cho: Choline, Cr: Creatine, Glx: glutamate + glutamine.


Supplementary Figure S1 Forest plots show the change of neurochemicals in hippocampus between MCI patients and HC subjects. (**A**) Data include 429 individuals from 7 studies for meta-analysis of Cho/Cr levels between MCI and HC. (**B**) Data include 465 individuals from 8 studies for meta-analysis mI/Cr levels between MCI and HC. (**C**) Data include 85 individuals from 3 studies for meta-analysis of mI/NAA levels between MCI and HC. (**D**) Data include 317 individuals from 4 studies for meta-analysis of Cho levels between MCI and HC. (**F**) Data include 317 individuals from 4 studies for meta-analysis of Cr levels between MCI and HC.



Supplementary Figure S2 Forest plots show the change of neurochemicals in hippocampus between AD patients and HC subjects. **(A)** Data include 604 individuals from 4 studies for meta-analysis of Cho/Cr levels between AD and HC. **(B)** Data include 584 individuals from 5 studies for meta-analysis mI/Cr levels between AD and HC. **(C)** Data include 352 individuals from 3 studies for meta-analysis of mI/NAA levels between AD and HC. **(D)** Data include 829 individuals from 4 studies for meta-analysis of NAA levels between AD and HC. **(E)** Data include 609 individuals from 3 studies for meta-analysis of Cho levels between AD and HC. **(F)** Data include 609 individuals from 3 studies for meta-analysis of Cr levels between AD and HC.




Supplementary Figure S3 Forest plots show the changes of NAA/Cr and NAA in medial temporal lobe between AD patients and HC subjects. **(A)** Data include 333 individuals from 4 studies for meta-analysis of NAA/Cr levels between AD and HC. **(B)** Data include 509 individuals from 4 studies for meta-analysis NAA levels between AD and HC.




В									
Study	N	AD Mean	SD	N	HC Mean	SD	Medial temporal lob NAA	e Hedges's g with 95% CI	Weight (%)
Jessen et al. 2005	33	10.700	1.760	23	12.200	1.790		-0.83 [-1.38, -0.29]	11.48
Chao et al. 2005	48	1.860	0.483	48	2.405	0.560		-1.03 [-1.46, -0.61]	19.22
Schuff et al. 2002	112	1.805	0.453	108	2.290	0.503		-1.01 [-1.29, -0.73]	43.91
Jessen et al. 2009	95	11.700	2.400	42	13.300	3.200	 	-0.60 [-0.96, -0.23]	25.39
Overall							•	-0.89 [-1.08, -0.70]	
Heterogeneity: I ² =	17.73	%, H ² =	1.22						
Test of $\theta_i = \theta_j$: Q(3) = 3.6	55, p = 0.	30						
Test of $\theta = 0$: $z = -$	9.40, p	0.00 = 0.00							
						-]	.5 -15 0	.5	
							Decreases in AD	Increases in AD	


Supplementary Figure S4 Forest plots show the change of neurochemicals in posterior cingulate and temporal lobe between MCI, AD patients and HC subjects. (A) Data include 279 individuals from 4 studies for meta-analysis of mI/NAA levels between AD and HC. (B) Data include 1159 individuals from 12 studies for meta-analysis Cho/Cr levels between AD and HC. (C) Data include 120 individuals from 3 studies for meta-analysis of mI/NAA levels between AD and MCI. (D) Data include 841 individuals from 9 studies for meta-analysis of mI levels between MCI and HC. (E) Data include 662 individuals from 6 studies for meta-analysis of mI levels between AD and HC. (F) Data include 267 individuals from 5 studies for meta-analysis of NAA/Cr levels in temporal lobe between AD and HC.



Supplementary Figure S5 Forest plots show the change of NAA/Cr and NAA in parietal lobe between AD patients and HC subjects. **(A)** Data include 151 individuals from 3 studies for meta-analysis of NAA/Cr levels in the Parietal WM between AD and HC. **(B)** Data include 151 individuals from 3 studies for meta-analysis of NAA levels in the Parietal GM between AD and HC.



Supplementary Figure S6 Forest plots show the change of NAA and NAA/Cr in occipital lobe, anterior cingulate, temporo-parietal lobe and frontal region between AD patients and HC subjects. (A) Data include 199 individuals from 3 studies for meta-analysis of NAA levels in occipital lobe between AD and HC. (B) Data include 136 individuals from 3 studies for meta-analysis NAA/Cr levels in the anterior cingulate between AD and HC. (C) Data include 151 individuals from 4 studies for meta-analysis of NAA/Cr levels in temporo-parietal lobe between AD and HC. (D) Data include 151 individuals from 4 studies for meta-analysis of mI/Cr levels in temporo-parietal lobe between AD and HC. (E) Data include 125 individuals from 3 studies for meta-analysis of mI levels in temporo-parietal lobe between AD and HC. (F) Data include 198 individuals from 3 studies for meta-analysis of NAA levels in frontal GM between AD and HC.



Supplementary Figure S7 Forest plots show the change of NAA/Cr and mI/Cr in paratrigonal white matter lobe between MCI patients and HC subjects. **(A)** Data include 266 individuals from 3 studies for meta-analysis of NAA/Cr levels between MCI and HC. **(B)** Data include 266 individuals from 3 studies for meta-analysis mI/Cr levels in anterior cingulate cortex between AD and HC.

